Evidence map›Paper›PMID 38305390›Full record

ArticleAnti-cancer agents in medicinal chemistry2024

Synthesis of a Novel Gold(I) Complex and Evaluation of Its Anticancer Properties in Breast Cancer Cells.

Haseeb Ahmad Khan, Anvarhusein Abdulkadir Isab, Abdullah Saleh Alhomida, Mansour Khalil Gatasheh, Ali Rashid Alhoshani, Bashayr Ahmed Aldhafeeri, N Rajendra Prasad

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Anti-cancer agents in medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Haseeb Ahmad KhanDepartment of Biochemistry, College of Science, King Saud University, Riyadh, 11451, Saudi Arabia.ORCID 0000-0001-6084-8589
Anvarhusein Abdulkadir IsabDepartment of Chemistry, College of Science, King Fahd University of Petroleum and Minerals, Dhahran, Saudi Arabia.
Abdullah Saleh AlhomidaDepartment of Biochemistry, College of Science, King Saud University, Riyadh, 11451, Saudi Arabia.
Mansour Khalil GatashehDepartment of Biochemistry, College of Science, King Saud University, Riyadh, 11451, Saudi Arabia.
Ali Rashid AlhoshaniDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia.
Bashayr Ahmed AldhafeeriDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia.
N Rajendra PrasadDepartment of Biochemistry and Biotechnology, Faculty of Life Sciences, Annamalai University, Annamalai Nagar, India.

Funding

King Abdulaziz City for Science and Technology 14-BIO-865-02
6 · The paper itself

Abstract

backgroundPlatinum complexes are commonly used for cancer chemotherapy; however, they are not only highly-priced but also have various side effects. It is, therefore, important to design affordable anticancer drugs with minimal side effects.

methodsWe synthesized a new gold(I) complex, PF6{(BDPEA)(TPPMS) digold(I)} (abbreviated as PBTDG) and tested its cytotoxicity in MCF-7 breast cancer cells. We also evaluated the effects of PBTDG on mitochondrial membrane potential, generation of reactive oxygen species (ROS) and apoptosis in breast cancer cells.

resultsThe IC

conclusionThe lower concentration of PBTDG produced similar cytotoxicity and apoptotic effects that were caused by a comparatively higher concentration of known anticancer drug (sorafenib). The anticancer effects of PBTDG are attributed to its tendency to disrupt mitochondrial membrane potential, induction of apoptosis and generation of ROS. Further studies are warranted to test the anticancer effects of PBTDG in animal models of cancer.

Indexed as

Antineoplastic AgentsNeoplasmsAnimalsApoptosisCell Line, TumorHumansMCF-7 CellsMembrane Potential, MitochondrialReactive Oxygen SpeciesSorafenibAntineoplastic AgentsReactive Oxygen SpeciesSorafenibanticancerapoptosiscytotoxicityGold(I) complexmitochondrial membrane potentialreactive oxygen species.

Identifiers

PMID38305390
PMCPMC11092555

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.